Clinical trials: Multiple Primary Neoplasm
Epilepsy, Dravet Syndrome
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies
The purpose of this study is to investigate the effect on the frequency of all seizures (convulsive and drop) in participants treated with TAK-935 compared to placebo.
- Conditions
- Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome
- Trial name
- ELEKTRA (NCT03650452)
- Testing
- TAK-935
- Where
- 44 sites in United States, Australia and 6 more
- Volunteers
- 141 people
- Sponsor
- Takeda
C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN), Recurrent Glomerular Disease After Kidney Transplantation
A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients
To assess the efficacy and safety of pegcetacoplan for the prevention of recurrent C3G or primary IC-MPGN in kidney transplant recipients
- Trial name
- PRESERVE (NCT07898774)
- Testing
- Pegcetacoplan
- Where
- 33 sites in Brazil, Canada and 8 more
- Volunteers
- 30 people
- Sponsor
- Swedish Orphan Biovitrum
Multiple System Atrophy
"An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."
This expanded access protocol is part of IND 32226 to evaluate efficacy and safety of multiple intravenous administrations of allogeneic HB-adMSCs for the treatment of Multiple System Atrophy for up to 7 adult patients who pass…
- Trial name
- NCT07238062
- Testing
- HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells
- Where
- United States
- Sponsor
- Hope Biosciences Research Foundation
Migraine
Double-blind, Placebo-controlled Study of BGC20-1531 in Migraine
The study is being conducted to explore the safety and effectiveness of a new chemical entity, BGC20-1531, in subjects with a history of migraine.
- Trial name
- NCT00888680
- Testing
- BGC20-1531, Lactose
- Where
- 4 sites in Denmark, Norway and 1 more
- Sponsor
- Boston Scientific Corporation
Liver Transplant
Efficacy and Safety of CertiroBell® Tablet Plus Tacrolimus in Primary Living Donor Liver Transplant Recipients
To evaluate the efficacy and safety of CertiroBell® tablet plus tacrolimus
- Trial name
- STELLA (NCT04867720)
- Testing
- Everolimus
- Where
- South Korea
- Volunteers
- 112 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Primary Open Angle Glaucoma, Ocular Hypertension
A Clinical Study to Evaluate the Efficacy and Safety of CKD-351
The purpose of this study is to evaluate efficacy and safety of CKD-351
- Trial name
- NCT04448223
- Testing
- CKD-351, Latanoprost+Dorzolmamide
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Chong Kun Dang Pharmaceutical
COVID-19
Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults
The purpose of this study is to assess the immunogenicity and safety of the investigational SCB-2019 vaccine, administered as a booster dose, to adults who: Received primary series with one of the selected authorized or…
- Trial name
- NCT05188677
- Testing
- Candidate vaccine, SCB-2019, Comirnaty Vaccine, Vaxzevria Vaccine
- Where
- 2 sites in Philippines
- Volunteers
- 1,831 people, healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
Comparison of the Extent to Which the Drug Given as Two Different Capsule Sizes Becomes Available to the Body
Researchers are looking for a new way to treat women who have symptoms by hormonal changes, like those that happen in women during menopause. These symptoms can include hot flashes, night sweats, and changes in blood pressure.
- Trial name
- NCT04845841
- Testing
- Elinzanetant (BAY3427080) treatment A, Elinzanetant (BAY3427080) treatment B
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bayer
Knee Osteoarthritis
A Multicenter Study of rhFGF 18 in Patients With Knee Osteoarthritis Not Requiring Surgery
Osteoarthritis (OA) is one of the most common diseases affecting the joints, usually those that are weight bearing such as the knees.
- Trial name
- NCT01033994
- Testing
- AS902330
- Where
- 28 sites in Bulgaria, Canada and 7 more
- Volunteers
- 192 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Blood Loss, Surgical
Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement
The purpose of this study is to assess if aprotinin (BAY A0128), given intravenously during surgery, is safe and can help reduce the amount of bleeding and the need for a blood transfusion during hip replacement surgery.
- Trial name
- NCT00668031
- Testing
- Trasylol (Aprotinin, BAYA0128)
- Where
- 40 sites in United States, Canada and 1 more
- Volunteers
- 359 people
- Sponsor
- Bayer
MPN (Myeloproliferative Neoplasms)
An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis
This is a study of itacitinib (INCB039110) in patients with myelofibrosis. This study will evaluate safety and efficacy parameters of itacitinib (INCB039110).
- Trial name
- NCT01633372
- Testing
- itacitinib
- Where
- 22 sites in United States, Australia and 1 more
- Volunteers
- 87 people
- Sponsor
- Incyte Corporation
Osteoarthritis, Rheumatoid Arthritis
Randomized Fixed Bearing vs Mobile Bearing Cruciate Retaining TKA
The purpose of this study is to evaluate the clinical performance of the rotating platform and fixed bearing implants in patients undergoing primary total knee replacement.
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Post-traumatic Arthritis, Juvenile Rheumatoid Arthritis
- Trial name
- NCT00289094
- Testing
- Total Knee Replacement
- Where
- 2 sites in United States
- Volunteers
- 99 people
- Sponsor
- DePuy Orthopaedics
Hypotension, Orthostatic
A Study for Patients With Neurogenic Orthostatic Hypotension
We are seeking male and female patients to voluntarily take part in a clinical research study. Patients must be aged 18 or older and diagnosed with symptomatic orthostatic hypotension (low blood pressure while in the upright…
- Trial name
- NCT00046475
- Testing
- Midodrine Hydrochloride
- Where
- 15 sites in United States
- Volunteers
- 140 people
- Sponsor
- Shire
Sleep Problems
Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances
There is increasing evidence that chronic sleep disorders in children with autism spectrum disorder (ASD), Angelman Syndrome (AS) and Smith-Magenis syndrome (SMS) are associated with disturbed melatonin secretion and melatonin…
- Trial name
- NCT01903681
- Testing
- Circadin 2 mg, Circadin 10 mg
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Ataxia Telangiectasia
Evaluate the Neurological Effects of EryDex on Subjects With A-T
This is an international, multi-center, randomized, prospective, double-blind, placebo-controlled, Phase 3 study, designed to assess the effect of EryDex (dexamethasone sodium phosphate [DSP] in autologous erythrocytes)…
- Trial name
- NEAT (NCT06193200)
- Testing
- Dexamethasone sodium phosphate
- Where
- 19 sites in United States, Denmark and 7 more
- Volunteers
- 105 people
- Sponsor
- Quince Therapeutics S.p.A.
Multiple Myeloma
Study Comparing STR (Skeletal Targeted Radiotherapy) Plus Melphalan to Melphalan Alone, With Stem Cell Transplant in Multiple Myeloma
STR (Skeletal Targeted Radiotherapy, 166Ho-DOTMP) is an investigational radiopharmaceutical that delivers radiation directly to cancer cells in the bone and bone marrow.
- Trial name
- NCT00083564
- Testing
- STR(TM) (Skeletal Targeted Radiotherapy, Holmium-166-DOTMP)
- Where
- 21 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Poniard Pharmaceuticals
Breast Neoplasm
Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women
The purpose of this study is to examine the effect of the combination of everolimus and letrozole compared to placebo and letrozole as pre-surgical therapy in patients with newly diagnosed estrogen receptor positive breast cancer.
- Trial name
- NCT00107016
- Testing
- RAD001, Letrozole 2.5mg, Letrozole 2.5mg
- Where
- 46 sites in United States, Austria and 8 more
- Volunteers
- 267 people
- Sponsor
- Novartis Pharmaceuticals
Fallopian Tube Cancer, Peritoneal Neoplasms
OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
The purpose of this project is to see if weekly carboplatin compared with phenoxodiol in combination with weekly carboplatin, is effective against late stage ovarian cancer and to see what, if any, side-effects of treatment may…
- Conditions
- Fallopian Tube Cancer, Peritoneal Neoplasms, Ovarian Cancer
- Trial name
- OVATURE (NCT00382811)
- Testing
- phenoxodiol, carboplatin
- Where
- 70 sites in United States, Australia and 5 more
- Volunteers
- 142 people
- Sponsor
- MEI Pharma, Inc.
Developmental and Epileptic Encephalopathy, Dravet Syndrome
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
The objective of this study is to assess the long-term safety, tolerability, and efficacy of adjunctive therapy of LP352 in subjects with developmental and epileptic encephalopathies who completed participation in Study LP352-201.
- Conditions
- Developmental and Epileptic Encephalopathy, Dravet Syndrome, Lennox-Gastaut Syndrome
- Trial name
- NCT05626634
- Testing
- LP352, bexicaserin
- Where
- 28 sites in United States, Australia
- Volunteers
- 41 people
- Sponsor
- Longboard Pharmaceuticals
Primary Insomnia
Comparison of Two Temperatures to Treat Insomnia
Insomnia patients demonstrate subjective and physiological hyperarousal. The Cereve Sleep System has been proposed as a clinical treatment to reverse this hyperarousal in insomnia patients.
- Trial name
- NCT01790256
- Testing
- Cereve Sleep System at 30 degrees C, Cereve Sleep System at 14-16 degrees C
- Where
- 9 sites in United States
- Volunteers
- 144 people
- Sponsor
- Cereve, Inc.